138 related articles for article (PubMed ID: 15501458)
1. WP744 is a novel anthracycline with enhanced activity against neuroblastoma.
Inge TH; Harris NL; Wu J; Azizkhan RG; Priebe W
J Surg Res; 2004 Oct; 121(2):187-96. PubMed ID: 15501458
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells.
Wu J; Harris NL; Inge TH
J Surg Res; 2004 Dec; 122(2):231-9. PubMed ID: 15555623
[TBL] [Abstract][Full Text] [Related]
3. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
[TBL] [Abstract][Full Text] [Related]
4. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
5. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
[TBL] [Abstract][Full Text] [Related]
6. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
[TBL] [Abstract][Full Text] [Related]
7. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
[TBL] [Abstract][Full Text] [Related]
8. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.
Hopkins-Donaldson S; Yan P; Bourloud KB; Muhlethaler A; Bodmer JL; Gross N
Oncogene; 2002 Sep; 21(39):6132-7. PubMed ID: 12203125
[TBL] [Abstract][Full Text] [Related]
11. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
12. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.
Wallick CJ; Gamper I; Thorne M; Feith DJ; Takasaki KY; Wilson SM; Seki JA; Pegg AE; Byus CV; Bachmann AS
Oncogene; 2005 Aug; 24(36):5606-18. PubMed ID: 16007177
[TBL] [Abstract][Full Text] [Related]
13. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.
Manohar CF; Bray JA; Salwen HR; Madafiglio J; Cheng A; Flemming C; Marshall GM; Norris MD; Haber M; Cohn SL
Oncogene; 2004 Jan; 23(3):753-62. PubMed ID: 14737110
[TBL] [Abstract][Full Text] [Related]
14. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW
Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630
[TBL] [Abstract][Full Text] [Related]
15. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.
Liontas A; Yeger H
Anticancer Res; 2004; 24(2B):987-98. PubMed ID: 15161054
[TBL] [Abstract][Full Text] [Related]
16. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
Kotchetkov R; Cinatl J; Blaheta R; Vogel JU; Karaskova J; Squire J; Hernáiz Driever P; Klingebiel T; Cinatl J
Int J Cancer; 2003 Mar; 104(1):36-43. PubMed ID: 12532417
[TBL] [Abstract][Full Text] [Related]
17. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
[TBL] [Abstract][Full Text] [Related]
18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
20. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
